Illinois Science + Technology Blog

September 2017

Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. The 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Lead programs address diseases from inflammatory disorders to oncology. SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure's intellectual property portfolio includes 125 pending patent applications and 45 allowed or issued patents.

Exicure, previously known as AuraSense Therapeutics has been at the Science Park for over 5 years. Exicure has a broad pipeline of SNA-based therapeutics to treat a range of diseases with great unmet medical needs. The company is moving a number of therapeutic targets from research to Phase 1 and Phase 2. Lab and office facilities have been enlarged.  Recently, Exicure expanded to new office space on the first floor of 8045 Lamon with labs on the fourth floor. To learn more about Exicure, click here.

Posted in:

Past Postings

July 2017

Vetter - Microdermics Agreement

Vetter, a leading and innovative provider of aseptic prefilled... Read on >

May 2017

Fresenius Kabi Acquisitions

Fresenius Kabi will strengthen and diversify its product portfolio... Read on >

April 2017

Vetter- Partnership - Key to Success

Flexibility, responsiveness and operational excellence are... Read on >